AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Operating Cash Flow

Cash generated by the company's core business operations during the period.

AC Immune S.A.NASDAQ: ACIU

Operating Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Operating cash flow turns negative

Q4 FY2025 operating cash flow was -CHF 16.45M, compared with CHF 5.93M a year earlier. Trailing-twelve-month operating cash flow was -CHF 69.2M. Over 3 fiscal years it compounded at -3.5% a year.

Context

  • Operating cash flow amounted to 1851.3% of revenue in FY2025, up 1610.2 pp from a year earlier.
  • Operating cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly operating cash flow holds near -CHF 16.45M or moves back toward the trailing-twelve-month quarterly average of -CHF 17.3M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CHF 16.45M-10.3% QoQ
Last fiscal yearDec 2025
-CHF 66.15M-200.5% YoY
LTMDec 2025
-CHF 69.2M-205.1% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-377.2%——
1 year-200.5%——
3-year CAGR-3.5%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

CHF · from the cash flow

Latest · FY2025
(66.15M) CHF
Year-over-year change
-200.5%

Operating Cash Flow vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -205.1% is the 8th highest of 9, against a peer median of -0.6%.
  • Operating cash flow amounts to 1936.8% of revenue for ACIU, versus a peer median of 5390.8%.
ACIU Competitors
Operating Cash Flow for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANNXAnnexon, Inc.LTM Mar 2026$183.1M USD+31.0%+17.0%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$133.8M USD-23.6%-4.0%431600.0%
ACIUAC Immune S.A.LTM Dec 2025CHF 69.2M CHF-205.1%-3.5%1936.8%
SLNSilence Therapeutics plcLTM Mar 2026$65.57M USD—+3.0%7115.1%
ANROAlto Neuroscience, Inc.LTM Mar 2026$62.3M USD+17.6%+36.4%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$57.17M USD+46.0%+40.1%—
CLLSCellectis S.A.LTM Mar 2026$37.91M USD-230.1%-22.9%55.7%
MREOMereo BioPharma Group plcLTM Mar 2026$26.95M USD-18.7%-14.1%5390.8%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$26.68M USD—+3.8%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$25.99M USD-43.1%-16.2%—
AMRNAmarin Corporation plcLTM Mar 2026$25.51M USD+182.6%—11.9%
Peer median (excluding ACIU) —-0.6%+3.0%5390.8%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.